Intracellular sequestration of anti-tumor drugs by metallothionein
1Dept of Chemistry and Biochemistry, University of Maryland Baltimore County, 21250, USA.
Abstract:
Acquired drug resistance is one of the most important problems in cancer chemotherapy. One of the mechanisms proposed to contribute to this phenomenon is the sequestration of alkylating agents by metallothionein (MT) in vivo. In this study cadmium-induced human bladder tumor T24 cells were exposed to the therapeutic agents chlorambucil and melphalan. MT-2a, was shown by capillary electrophoresis to comprise 56% of the MT isoforms in induced cells, and drug adducts of MT-2a were isolated and characterized by HPLC and electrospray ionization mass spectrometry. One to four equivalents of drug were found to be covalently adducted. Major binding sites on metallothionein were located in the C-terminal domain by peptide mapping, consistent with previous studies in vitro.
More Related Videos
Related Concept Videos
Antiprotozoal Agents
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Microbial Bioremediation of Uranium
Antibody Actions
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...


